Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem/progenitor cells (MSCs) are key players in regenerative medicine, relying principally on their differentiation/regeneration potential, immunomodulatory properties, paracrine effects, and potent homing ability with minimal if any ethical concerns. Even though multiple preclinical and clinical studies have demonstrated remarkable properties for MSCs, the clinical applicability of MSC-based therapies is still questionable. Several challenges exist that critically hinder a successful clinical translation of MSC-based therapies, including but not limited to heterogeneity of their populations, variability in their quality and quantity, donor-related factors, discrepancies in protocols for isolation, in vitro expansion and premodification, and variability in methods of cell delivery, dosing, and cell homing. Alterations of MSC viability, proliferation, properties, and/or function are also affected by various drugs and chemicals. Moreover, significant safety concerns exist due to possible teratogenic/neoplastic potential and transmission of infectious diseases. Through the current review, we aim to highlight the major challenges facing MSCs’ human clinical translation and shed light on the undergoing strategies to overcome them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 2×
“ASCs were originally described as a more convenient alternative to BMSCs [146] with less invasive isolation procedure [147], higher yield of progenitor cells [148, 149], and greater proliferation rate [145, 150].”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819 · cited 1×
“Challenges in defining an optimal cell dose for specific therapeutic applications are related to the large variabilities in MSC clinical trials, including different disease categories, study design, target tissue/organs, types of MSCs used, manufacturing protocols, routes of delivery, and dosing employed [495, 496].”
BackgroundCaplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Mechanical forces direct stem cell behaviour in development and regeneration
Vining, K. H., & Mooney, D. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.108 · Cited by 1,656
Cited by
The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
“MSCs isolated from different sources share many common characteristics, but they also show particular phenotypic and functional differences (Patel et al., 2016; Wu et al., 2018; Rady et al., 2020a; Shin et al., 2021; Li Y. et al., 2022; Li S. et al., 2022; Laloze et al., 2023).”
BackgroundMesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“Among them, MSCs can be successfully isolated and expanded from several common sources [188], i.”
BackgroundMinev, T., Balbuena, S., Gill, J. M., Marincola, F. M., Kesari, S., & Lin, F. (2024) · Oncotarget · doi:10.18632/oncotarget.28672 · Cited by 34
“Furthermore, the proliferative capacity of MSCs, combined with genetic modifications, raises concerns about the potential for uncontrolled cell growth and tumorigenicity [64].”
Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review
Wu, K.-C., Chang, Y.-H., Ding, D.-C., & Lin, S.-Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312911 · Cited by 33
“Despite these advancements, challenges persist in clinical translation, such as population heterogeneity, variability in isolation and expansion protocols, and safety concerns regarding teratogenic potential [99].”
Metadata
- Authors
- Rady, D., Abbass, M. M. S., El-Rashidy, A. A., El Moshy, S., Radwan, I. A., Dörfer, C. E., & Fawzy El-Sayed, K. M.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2020-08-11
- Volume
- 2020
- Pages
- 1-45
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W3048635192
- Cited by
- 68
- References
- 42
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation. https://app.cochat.ai/papers/10.1155/2020/8837654
- The paper
- Rady, D., Abbass, M. M. S., El-Rashidy, A. A., El Moshy, S., Radwan, I. A., Dörfer, C. E., & Fawzy El-Sayed, K. M. (2020). Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation. Stem Cells International. https://doi.org/10.1155/2020/8837654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.